SSA
UBX

Schonfeld Strategic Advisors’s Unity Biotechnology UBX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,000
Closed -$38.4K – 2667
2022
Q4 		$38.4K Buy
+14,000
New +$40.7K ﹤0.01% 2279
2022
Q2 		– Sell
-3,870
Closed -$43K – 3010
2022
Q1 		$43K Buy
+3,870
New +$43.4K ﹤0.01% 2357
2021
Q4 		– Sell
-1,420
Closed -$43K – 2556
2021
Q3 		$43K Sell
1,420
-370
-21% -$13.1K ﹤0.01% 2009
2021
Q2 		$83K Buy
+1,790
New +$86.2K ﹤0.01% 1846
2020
Q4 		– Sell
-3,360
Closed -$116K – 1900
2020
Q3 		$116K Buy
+3,360
New +$213K ﹤0.01% 1258

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schonfeld Strategic Advisors's UBX Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Unity Biotechnology (UBX) in Q1 2023, closing a stake of 14,000 shares — an estimated $38.4K sold.

Schonfeld Strategic Advisors first reported a position in UBX in Q3 2020 and held it in 5 quarters. The position peaked at $116K in Q3 2020. 46 funds tracked by Wall St. Rank hold UBX as of Q1 2023.

  • Schonfeld Strategic Advisors reported no remaining Unity Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 14,000 Unity Biotechnology shares in Q1 2023, an estimated $38.4K.
  • Schonfeld Strategic Advisors first reported a position in Unity Biotechnology in Q3 2020 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Unity Biotechnology position peaked at $116K in Q3 2020.
  • 46 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.